Clinical trials: Refractory Brain Neoplasm
Tuberous Sclerosis Complex, Aspirin
Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
There had been much evidence in aspirin controlling tumorous conditions conducted by basic researches, especially through mammilian target of rapamycin (mTOR) pathway.
- Conditions
- Tuberous Sclerosis Complex, Aspirin, Epilepsy, Cognitive Decline
- Trial name
- NCT03356769
- Testing
- Aspirin, AED
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Peking Union Medical College Hospital
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Ovarian Cancer
- Trial name
- NCT00003173
- Testing
- filgrastim, thiotepa, autologous bone marrow transplantation
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma Multiforme, Glioma of Brain
V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer
The Phase II study to determine the safety and efficacy of V-Boost in treating a type of brain cancer called Glioblastoma Multiforme (GBM).
- Trial name
- GBM (NCT03916757)
- Testing
- V-Boost
- Where
- Mongolia
- Volunteers
- 20 people
- Sponsor
- Immunitor LLC
Brain Stem Neoplasm, Pineal Region Neoplasm
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment.
- Conditions
- Brain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT02780804
- Testing
- Entinostat, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 21 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
RATIONALE: Talabostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide and carboplatin, work in different ways to stop the growth of tumor…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Kidney Cancer, Liver Cancer
- Trial name
- NCT00303940
- Testing
- carboplatin, talabostat mesylate, temozolomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Lymphoma, Neuroblastoma
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
This research study is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain tumors.
- Conditions
- Lymphoma, Neuroblastoma, Brain Tumor, Solid Tumor
- Trial name
- NCT02909777
- Testing
- CUDC-907
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dana-Farber Cancer Institute
Pediatric Solid Tumor, Refractory Tumor
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
- Conditions
- Pediatric Solid Tumor, Refractory Tumor, Recurrent Tumor, CNS Malignancies
- Trial name
- NCT02564198
- Testing
- Ramucirumab
- Where
- 21 sites in United States
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
This phase I trial is studying the side effects and best dose of pazopanib hydrochloride in treating young patients with solid tumors that have relapsed or not responded to treatment.
- Conditions
- Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT00929903
- Testing
- pazopanib hydrochloride, pharmacological study
- Where
- 14 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Recurrent Brain Neoplasm
Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of dasatinib and temsirolimus when given together with cyclophosphamide in treating patients with solid tumors that have spread to other places in the body, have come…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Brain Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Brain Neoplasm
- Trial name
- NCT02389309
- Testing
- Cyclophosphamide, Dasatinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Tumor, Recurrent, Brain Tumor, Refractory
T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors
This study is for patients that have brain cancer. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers.
- Trial name
- iCAR (NCT02442297)
- Testing
- HER2-specific T cells
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Baylor College of Medicine
Childhood Cancer, Childhood Solid Tumor
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
A companion platform trial to test novel targeted agents based on the patient's tumor profile.
- Conditions
- Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Recurrent Cancer
- Trial name
- NCT06208657
- Testing
- Paxalisib, Opdualag, Irinotecan (drug)
- Where
- 14 sites in Australia, Canada
- Volunteers
- 90 people
- Sponsor
- Australian & New Zealand Children's Haematology/Oncology Group
Solid Tumors, Brain Tumors
Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
Background: Cisplatin and carboplatin are standard cancer treatment drugs used for various childhood cancers, including brain tumors.
- Conditions
- Solid Tumors, Brain Tumors, Brain Metastases
- Trial name
- NCT01259479
- Testing
- Satraplatin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Cancer, Refractory Neoplasm
9-ING-41 in Pediatric Patients With Refractory Malignancies.
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
- Conditions
- Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor
- Trial name
- NCT04239092
- Testing
- 9-ING-41, Irinotecan, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Actuate Therapeutics Inc.
Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
This phase I trial is studying the side effects and best dose of erlotinib when given with temozolomide in treating young patients with recurrent or refractory solid tumors.
- Conditions
- Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma
- Trial name
- NCT00077454
- Testing
- erlotinib hydrochloride, temozolomide, pharmacological study
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Cancer, Childhood Solid Tumor
PRecISion Medicine for Children With Cancer
This is a multicentre prospective study of the feasibility and clinical value of a diagnostic service for identifying therapeutic targets and recommending personalised treatment for children and adolescents with high-risk cancer.
- Conditions
- Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Childhood Leukemia
- Trial name
- PRISM (NCT03336931)
- Testing
- Molecular profiling and drug testing
- Where
- 8 sites in Australia
- Volunteers
- 550 people
- Sponsor
- Sydney Children's Hospitals Network
Brain Tumor, Central Nervous System Tumors
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in children with cancer. PURPOSE: This phase II trial is studying how well cyproheptadine and megestrol work in improving appetite and…
- Conditions
- Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia
- Trial name
- NCT00066248
- Testing
- cyproheptadine hydrochloride, megestrol acetate
- Where
- 43 sites in United States, Canada and 1 more
- Volunteers
- 70 people
- Sponsor
- University of South Florida
Ewing Sarcoma, Solid Tumors
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults…
- Conditions
- Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma
- Trial name
- NCT03709680
- Testing
- Palbociclib, Temozolomide, Irinotecan
- Where
- 84 sites in United States, Brazil and 11 more
- Volunteers
- 128 people
- Sponsor
- Pfizer
Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors.
- Conditions
- Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma
- Trial name
- NCT00095940
- Testing
- lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with recurrent, progressive, or refractory CNS tumors.
- Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma
- Trial name
- NCT00100880
- Testing
- lenalidomide, perfusion-weighted magnetic resonance imaging, diffusion-weighted magnetic resonance imaging
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors, Brain Tumors
NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors
BACKGROUND: Despite progress, some children and young adults with solid tumors still experience poor survival. Activated NK cells potently kill autologous pediatric solid tumors, and clinical grade procedures are available to…
- Conditions
- Solid Tumors, Brain Tumors, Sarcoma, Pediatric Cancers
- Trial name
- NCT01875601
- Testing
- Recombinant human interleukin-15 (rhIL-15), NK Cell Infusion
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)